Justempa 10 Tablet contains Empagliflozin 10 mg, an oral antihyperglycemic agent belonging to the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors. It is primarily indicated for the management of type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control. Empagliflozin works by inhibiting SGLT2 in the proximal renal tubules, reducing glucose reabsorption and increasing urinary glucose excretion, thereby lowering plasma glucose levels. The medication has demonstrated efficacy in reducing HbA1c levels and promoting modest weight loss and blood pressure reduction, contributing to improved cardiovascular outcomes in patients with type 2 diabetes at high cardiovascular risk. Justempa 10 Tablet is typically administered once daily, with or without food. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal impairment, or hypersensitivity to the active substance. Common adverse effects include urinary tract infections, genital mycotic infections, and increased urination. Patients should be monitored for signs of volume depletion and renal function periodically during therapy. Justempa 10 Tablet should be used cautiously in patients with risk factors for hypotension or electrolyte imbalance. It is essential to adhere to prescribed dosing and lifestyle modifications to achieve optimal therapeutic outcomes.